Literature DB >> 17330407

Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody.

Scott K Kuwada1.   

Abstract

PDL Biopharma Inc (formerly Eos Biotechnology Inc) and Biogen Idec Inc are developing volociximab, an angiogenesis-inhibiting chimeric mAb that targets AAB1, a component protein of alpha5/beta1 integrin, for the potential treatment of solid tumors, including renal cell carcinoma. Two phase II clinical trials evaluating volociximab in solid tumors are underway. Volociximab is also under investigation for the treatment of age-related macular degeneration.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17330407

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  16 in total

1.  Integrin targeted therapeutics.

Authors:  Melissa Millard; Srinivas Odde; Nouri Neamati
Journal:  Theranostics       Date:  2011-02-17       Impact factor: 11.556

2.  Targeting angiogenesis in melanoma: prospects for the future.

Authors:  P G Corrie; B Basu; K Ahmad Zaki
Journal:  Ther Adv Med Oncol       Date:  2010-11       Impact factor: 8.168

Review 3.  Integrins and metastasis.

Authors:  Kirat Kumar Ganguly; Sekhar Pal; Shuvojit Moulik; Amitava Chatterjee
Journal:  Cell Adh Migr       Date:  2013-04-05       Impact factor: 3.405

4.  Importance of interaction between nerve growth factor and α9β1 integrin in glial tumor angiogenesis.

Authors:  Erin M Walsh; Richard Kim; Luis Del Valle; Michael Weaver; Joel Sheffield; Philip Lazarovici; Cezary Marcinkiewicz
Journal:  Neuro Oncol       Date:  2012-05-17       Impact factor: 12.300

Review 5.  Integrins in cancer: biological implications and therapeutic opportunities.

Authors:  Jay S Desgrosellier; David A Cheresh
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

6.  Integrins in tumor angiogenesis and lymphangiogenesis.

Authors:  Philippe Foubert; Judith A Varner
Journal:  Methods Mol Biol       Date:  2012

Review 7.  Angiogenesis in cancer: Anti-VEGF escape mechanisms.

Authors:  Gerald W Prager; Marina Poettler; Matthias Unseld; Christoph C Zielinski
Journal:  Transl Lung Cancer Res       Date:  2012-03

8.  alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer.

Authors:  Jesse Roman; Jeffrey D Ritzenthaler; Sussane Roser-Page; XiaoJuan Sun; ShouWei Han
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-15       Impact factor: 6.914

Review 9.  Matrix control of pancreatic cancer: New insights into fibronectin signaling.

Authors:  Mary Topalovski; Rolf A Brekken
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 10.  Integrins in angiogenesis and lymphangiogenesis.

Authors:  Christie J Avraamides; Barbara Garmy-Susini; Judith A Varner
Journal:  Nat Rev Cancer       Date:  2008-05-22       Impact factor: 60.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.